FANJ
GNMX

Financial Architects (New Jersey)’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Financial Architects (New Jersey)’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,000
Closed -$37K – 1050
2015
Q2 		$37K Buy
+6,000
New +$46.5K 0.01% 502

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Architects (New Jersey)'s GNMX Position: Q3 2015 in Review

Financial Architects (New Jersey) sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2015, closing a stake of 6,000 shares — an estimated $37K sold.

Financial Architects (New Jersey) first reported a position in GNMX in Q2 2015 and held it in 1 quarter. The position peaked at $37K in Q2 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q3 2015.

  • Financial Architects (New Jersey) reported no remaining Aevi Genomic Medicine Inc position as of Q3 2015 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 6,000 Aevi Genomic Medicine Inc shares in Q3 2015, an estimated $37K.
  • Financial Architects (New Jersey) first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Aevi Genomic Medicine Inc position peaked at $37K in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2015.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2015, filed 13 Nov 2015.